Baird lowered the firm’s price target on Merit Medical (MMSI) to $104 from $108 and keeps an Outperform rating on the shares. The firm updated its model following the company’s 2026 organic growth outlook which makes a case for multiple expansion.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MMSI:
- Merit Medical price target raised to $109 from $106 at Barrington
- Merit Medical Systems: Strong Q4 Beat, Upbeat 2026 Outlook, and Margin Expansion Underpin Buy Rating Despite Lowered Price Target
- Merit Medical Posts Strong Q4 Results, Raises 2026 Outlook
- Merit Medical reports Q4 EPS $1.04, consensus 95c
- Merit Medical sees FY26 EPS $4.01-$4.15, consensus $4.04